title: T-cell depletion of HLA-identical transplants in leukemia.
abstract: We analyzed the effects of T-cell depletion on the outcome of HLA-identical sibling bone marrow transplants for leukemia by comparing 731 T-cell-depleted transplants with 2,480 non-T-cell-depleted transplants. T-cell depletion decreased acute graft-versus-host disease (GVHD) (relative risk [RR] 0.45; P less than .0001) and chronic (GVHD) (RR 0.56; P less than .0001). However, it increased graft failure (RR 9.29; P less than .0001). Leukemia relapse also was increased. In first remission acute leukemia or chronic phase chronic myelogenous leukemia, leukemia relapse was 2.75 times more likely after T-cell-depleted transplants (P less than .0001). T-cell depletion increased the risk of treatment failure (RR 1.35; P less than .0003) and decreased leukemia-free survival. We also studied controllable variables associated with outcome of T-cell-depleted transplants. The unique findings were that among recipients of T-cell-depleted transplants for early leukemia, radiation doses greater than or equal to 11 Gy (RR 0.54; P less than .01), dose rates greater than 14 cGy/min (RR 0.56; P less than .002), and additional posttransplant immune suppression with cyclosporine alone (RR 0.53; P less than .0006) or cyclosporine plus methotrexate (RR 0.36; P less than .01) were associated with fewer treatment failures. Use of monoclonal antibodies rather than physical techniques for T-cell depletion (RR 2.01; P less than .03) and fractionated radiation (RR 1.69; P less than .05) were associated with increased treatment failure and lower leukemia-free survival. These data may be useful in designing strategies to improve results of T-cell-depleted transplants.
authors.affiliation: Department of Medicine, Medical College of Wisconsin, Milwaukee.
authors.forename: A M
authors.initials: AM
authors.lastname: Marmont
authors.forename: M M
authors.initials: MM
authors.lastname: Horowitz
authors.forename: R P
authors.initials: RP
authors.lastname: Gale
authors.forename: K
authors.initials: K
authors.lastname: Sobocinski
authors.forename: R C
authors.initials: RC
authors.lastname: Ash
authors.forename: D W
authors.initials: DW
authors.lastname: van Bekkum
authors.forename: R E
authors.initials: RE
authors.lastname: Champlin
authors.forename: K A
authors.initials: KA
authors.lastname: Dicke
authors.forename: J M
authors.initials: JM
authors.lastname: Goldman
authors.forename: R A
authors.initials: RA
authors.lastname: Good
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D006084:Graft Rejection; D006086:Graft vs Host Disease / Q000517:prevention & control; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000188:drug therapy / Q000601:surgery*; D008212:Lymphocyte Depletion; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes
chemical_list: D006680:HLA Antigens